.svg){kind=small}
DIA 3rd Cardiac Safety Workshop Explores the Future of the TQT Study And Issues Surrounding the Conduct and Analysis of TQT Studies in Japan
9
May 2012
Cardiovascular Safety and State-of-the-art Development Issues 2012: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity
19
March 2012
QT Assessment in Early Clinical Development Can the Predictive Value be Enhanced to be Similar to That of a TQT study?
15
January 2012
Further data to be presented at The 32nd Annual Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)
29
November 2011
Richmond Pharmacology enhances its established GE MUSE platform with the State-of-the-art Mortara 12-lead telemetry setup
8
November 2011
-min.jpg)
.jpg)
Latest news
Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director
August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read moreRed4Research Blog – Alan’s Story
June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read moreEvents
JSCPT 2025
5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event
